Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.80 |
| ▸ | MMP13 | P45452 | 17/20 | 0.80 |
| ▸ | MMP9 | P14780 | 16/20 | 0.80 |
| ▸ | MMP1 | P03956 | 16/20 | 0.80 |
| ▸ | MMP7 | P09237 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937324 | 0.92 | ADAM17 (0.82) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL3940997 | 0.92 | ADAM17 (0.82) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL3940092 | 0.89 | ADAM17 (0.83) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL3946257 | 0.89 | ADAM17 (1.00) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL4149331 | 0.89 | ADAM17 (0.80) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL3949946 | 0.89 | ADAM17 (0.77) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL3946205 | 0.89 | ADAM17 (0.82) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL6508164 | 0.89 | ADAM17 (0.76) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL6508065 | 0.88 | ADAM17 (0.75) | ADAM17MMP13MMP9MMP1MMP7 | |
| SCHEMBL6500168 | 0.88 | ADAM17 (0.75) | ADAM17MMP13MMP9MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP9 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.